259 related articles for article (PubMed ID: 29110224)
1. Role of VEGF, CD105, and CD31 in the Prognosis of Colorectal Cancer Cases.
Mohamed SY; Mohammed HL; Ibrahim HM; Mohamed EM; Salah M
J Gastrointest Cancer; 2019 Mar; 50(1):23-34. PubMed ID: 29110224
[TBL] [Abstract][Full Text] [Related]
2. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.
Miyata Y; Mitsunari K; Asai A; Takehara K; Mochizuki Y; Sakai H
Prostate; 2015 Jan; 75(1):84-91. PubMed ID: 25307287
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody.
Yao Y; Kubota T; Takeuchi H; Sato K
Neuropathology; 2005 Sep; 25(3):201-6. PubMed ID: 16193836
[TBL] [Abstract][Full Text] [Related]
4. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors.
Basilio-de-Oliveira RP; Pannain VL
World J Gastroenterol; 2015 Jun; 21(22):6924-30. PubMed ID: 26078569
[TBL] [Abstract][Full Text] [Related]
5. CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34.
Miyata Y; Sagara Y; Watanabe S; Asai A; Matsuo T; Ohba K; Hayashi T; Sakai H
Virchows Arch; 2013 Nov; 463(5):673-9. PubMed ID: 23975255
[TBL] [Abstract][Full Text] [Related]
6. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
Randall LM; Monk BJ; Darcy KM; Tian C; Burger RA; Liao SY; Peters WA; Stock RJ; Fruehauf JP
Gynecol Oncol; 2009 Mar; 112(3):583-9. PubMed ID: 19110305
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma.
Raica M; Cimpean AM; Anghel A
Neoplasma; 2007; 54(4):278-84. PubMed ID: 17822316
[TBL] [Abstract][Full Text] [Related]
8. CD105- and CD31-assessed microvessel density in laryngeal carcinoma biopsies as a predictor of recurrence after exclusive primary surgery.
Franz L; Alessandrini L; Saccardo T; Frigo AC; Marioni G
Ann Diagn Pathol; 2020 Oct; 48():151608. PubMed ID: 32890907
[TBL] [Abstract][Full Text] [Related]
9. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
[TBL] [Abstract][Full Text] [Related]
10. Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma.
Sakurai T; Okumura H; Matsumoto M; Uchikado Y; Owaki T; Kita Y; Setoyama T; Omoto I; Kijima Y; Ishigami S; Natsugoe S
Anticancer Res; 2014 Jul; 34(7):3431-8. PubMed ID: 24982351
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.
Rossi B; Schinzari G; Maccauro G; Scaramuzzo L; Signorelli D; Rosa MA; Fabbriciani C; Carlo B
BMC Musculoskelet Disord; 2010 Feb; 11():34. PubMed ID: 20158913
[TBL] [Abstract][Full Text] [Related]
12. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.
Yao Y; Pan Y; Chen J; Sun X; Qiu Y; Ding Y
Ann Clin Lab Sci; 2007; 37(1):39-48. PubMed ID: 17311868
[TBL] [Abstract][Full Text] [Related]
13. [Relevance of Endoglin (CD105) VEGF and p53 with invasion metastasis and prognosis of laryngeal carcinoma].
Li Q; Zhang B; Peng P
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Dec; 21(24):1114-7. PubMed ID: 18330257
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.
Mineo TC; Ambrogi V; Baldi A; Rabitti C; Bollero P; Vincenzi B; Tonini G
J Clin Pathol; 2004 Jun; 57(6):591-7. PubMed ID: 15166262
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of endoglin (CD105) expression in ovarian carcinoma.
Taskiran C; Erdem O; Onan A; Arisoy O; Acar A; Vural C; Erdem M; Ataoglu O; Guner H
Int J Gynecol Cancer; 2006; 16(5):1789-93. PubMed ID: 17009973
[TBL] [Abstract][Full Text] [Related]
16. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma.
Behrem S; Zarkovic K; Eskinja N; Jonjic N
Croat Med J; 2005 Jun; 46(3):417-22. PubMed ID: 15861521
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Endoglin as an Angiogenesis Marker in Glioblastoma.
Afshar Moghaddam N; Mahsuni P; Taheri D
Iran J Pathol; 2015; 10(2):89-96. PubMed ID: 26351468
[TBL] [Abstract][Full Text] [Related]
18. Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance.
Yu JX; Zhang XT; Liao YQ; Zhang QY; Chen H; Lin M; Kumar S
World J Gastroenterol; 2003 Dec; 9(12):2866-9. PubMed ID: 14669355
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma.
Di Paolo V; Russo I; Boldrini R; Ravà L; Pezzullo M; Benedetti MC; Galardi A; Colletti M; Rota R; Orlando D; Crocoli A; Peinado H; Milano GM; Di Giannatale A
BMC Cancer; 2018 Jan; 18(1):31. PubMed ID: 29304781
[TBL] [Abstract][Full Text] [Related]
20. CD105 expression is an independent predictor of survival in patients with endometrial cancer.
Erdem O; Taskiran C; Onan MA; Erdem M; Guner H; Ataoglu O
Gynecol Oncol; 2006 Dec; 103(3):1007-11. PubMed ID: 16854456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
